Investors Buy Eli Lilly And Co (LLY) on Weakness Following Insider Selling

Investors purchased shares of Eli Lilly And Co (NYSE:LLY) on weakness during trading hours on Tuesday following insider selling activity. $218.44 million flowed into the stock on the tick-up and $119.06 million flowed out of the stock on the tick-down, for a money net flow of $99.38 million into the stock. Of all companies tracked, Eli Lilly And Co had the 3rd highest net in-flow for the day. Eli Lilly And Co traded down ($4.12) for the day and closed at $119.96Specifically, insider Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 10,000 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $124.65, for a total transaction of $1,246,500.00. Following the transaction, the senior vice president now owns 57,806 shares of the company’s stock, valued at $7,205,517.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,003,959 shares of company stock worth $125,426,338. 0.11% of the stock is owned by insiders.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price objective for the company in a report on Wednesday, April 10th. Guggenheim lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a research note on Thursday, April 11th. Barclays reissued a “buy” rating and issued a $140.00 price objective on shares of Eli Lilly And Co in a research note on Sunday. Credit Suisse Group set a $121.00 price objective on shares of Eli Lilly And Co and gave the company a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, December 19th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly And Co currently has an average rating of “Buy” and an average target price of $118.02.

The company has a market capitalization of $127.47 billion, a PE ratio of 21.61, a price-to-earnings-growth ratio of 2.33 and a beta of 0.33. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same period in the prior year, the business earned $1.14 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in LLY. Bank of New York Mellon Corp increased its holdings in shares of Eli Lilly And Co by 0.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock valued at $1,019,568,000 after acquiring an additional 27,009 shares during the last quarter. Caxton Associates LP bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth approximately $250,000. Mutual Advisors LLC raised its position in Eli Lilly And Co by 36.9% in the 3rd quarter. Mutual Advisors LLC now owns 9,038 shares of the company’s stock valued at $970,000 after purchasing an additional 2,438 shares during the last quarter. Mackenzie Financial Corp raised its position in Eli Lilly And Co by 23.1% in the 3rd quarter. Mackenzie Financial Corp now owns 53,850 shares of the company’s stock valued at $5,779,000 after purchasing an additional 10,109 shares during the last quarter. Finally, HPM Partners LLC raised its position in Eli Lilly And Co by 8.3% in the 3rd quarter. HPM Partners LLC now owns 7,170 shares of the company’s stock valued at $769,000 after purchasing an additional 549 shares during the last quarter. 79.58% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Investors Buy Eli Lilly And Co (LLY) on Weakness Following Insider Selling” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2019/04/16/investors-buy-eli-lilly-and-co-lly-on-weakness-following-insider-selling.html.

Eli Lilly And Co Company Profile (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Moving Average Convergence Divergence (MACD)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit